Samsung Bioepis commences revocation suit against Fresenius Kabi adalimumab formulation patent

Revocation proceedings were commenced in the Federal Court by Samsung Bioepis on a Fresenius Kabi adalimumab formulation and use patent AU2015263246 (‘246).  The 246 patent covers a specific formulation of adalimumab with a histidine buffer, sugar, surfactant and pH, and use of that formulation.